91239-98-4

Usage

Uses

Used in Pharmaceutical Production:
3-[(ethylamino)methyl]phenol is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic effects.
Used in Organic Synthesis:
As a building block in organic synthesis, 3-[(ethylamino)methyl]phenol is utilized to create a variety of organic compounds, expanding the scope of chemical research and product development.
Used in Chemical Reactions as a Reagent:
3-[(ethylamino)methyl]phenol serves as a reagent in various chemical reactions, facilitating the synthesis of target compounds and contributing to the advancement of chemical processes.
Used in Medicine and Biotechnology:
Due to its unique chemical properties, 3-[(ethylamino)methyl]phenol has potential applications in the fields of medicine and biotechnology, where it may be employed in the development of innovative treatments and technologies.

Upstream product

• 213891-20-4 3-[(E)-Ethyliminomethyl]-phenol 
• 100-83-4 meta-hydroxybenzaldehyde 
• 75-04-7 ethylamine 

Downstream Products

• 90726-32-2 3--cyclohexanol 
• 134865-55-7 (E)-N-(3-chloropropenyl)-N-ethyl-3-hydroxybenzylamine 
• 213891-16-8 3-[N-ethyl-N-(3-hydroxybenzyl)amino]propoxyxanthen-9-one 
• 123944-74-1 (E)-N-ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-hydroxybenzylamine 
• 168414-39-9 (E)-N-ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-<((4-bromophenyl)dimethylsilyl)methoxy>benzylamine 

Relevant academic research and scientific papers

SULFONYLAMINO-ACETIC ACID DERIVATIVES

The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.

Acetylcholinesterase inhibitors: Synthesis and structure-activity relationships of ω-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl derivatives

Acetylcholinesterase (ACHE) inhibitors are one of the most actively investigated classes of compounds in the search for an effective treatment of Alzheimer's disease. This work describes the synthesis, AChE inhibitory activity, and structure-activity relationships of some compounds related to a recently discovered series of AChE inhibitors: the ω-[N-methyl-N-(3- alkylcarbamoyloxyphenyl)methyl]aminoalkoxyxanthen-9-ones. The influence of structural variations on the inhibitory potency was carefully investigated by modifying different parts of the parent molecule, and a theoretical model of the binding of one representative compound to the enzyme was developed. The biological properties of the series were investigated in some detail by considering not only the activity on isolated enzyme but the selectivity with respect to butyrylcholinesterase (BuChE) and the in vitro inhibitory activity on rat cerebral cortex as well. Some of the newly synthesized derivatives, when tested on isolated and/or AChE-enriched rat brain cortex fraction, displayed a selective inhibitory activity and were more active than physostigmine. In particular, compound 13, an azaxanthone derivative, displayed the best rat cortex AChE inhibition (190-fold higher than physostigmine), as well as a high degree of enzyme selectivity (over 60-fold more selective for AChE than for BuChE). When tested in the isolated enzyme, compound 13 was less active, suggesting some differences either in drug availability/biotransformation or in the inhibitor-sensitive residues of the enzyme when biologically positioned in rat brain membranes.

(Aryloxy)methylsilane Derivatives as New Cholesterol Biosynthesis Inhibitors: Synthesis and Hypocholesterolemic Activity of a New Class of Squalene Epoxidase Inhibitors

A series of 3-substituted (aryloxy)silane derivatives of benzylamine (4' 4', or 4") was synthesized and evaluated for hypocholesterolemic activity.Most of the new silane derivatives were identified as potent inhibitors of pig liver squalene epoxidase with